 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's
terms of use. It may require cleanup to comply with Wikipedia's
content policies, particularly
neutral point of view. (July 2019) |
| Company type | Public |
|---|---|
| DSE: BEACONPHAR, CSE: BEACONPHAR | |
| Industry |
Pharmaceutics Biotechnology |
| Founded | 2006 |
| Headquarters | , Bangladesh |
Key people | Mohammad Ebadul Karim Bulbul, ( MD) |
| Products | Sofosvel, Darvoni, Tagrix, Crizonix, Daclavir, Soforal, Afanix, Axinix, Brigaix, Baricinix, Cabozanix, Dasanix, Hernix, Elbonix, Ibrutix, Lenvanix, Palbonix, Regonix, Tofacinix, and Wedica |
| Revenue |  US$56 million (2019) |
 US$27 million (2019) | |
| US$4 million (2019) | |
| Total assets | US$100 million (2021 |
Number of employees | 4,000 (2021) |
| Website |
beaconpharma |
Beacon Pharmaceuticals PLC is a Bangladeshi pharmaceutical company that develops generic version of medications.
Beacon manufactures more than 200 generic drugs and 65 oncology products. Beacon is the first company in Bangladesh to start export of cancer drugs. [1] [2] The company is exporting its products to Asia, Africa, Europe and Latin America. Beacon is public limited company listed in Dhaka & Chittagong stock exchange. About 2000 people are working in this company. [3] [4] [5]
Beacon has introduced a number of global first generics. [6]
The company's commercially available products include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir, osimertinib, crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib, and trelagliptin.
BEACON Medicare Limited(BML) [7] is the exclusive global marketing & distribution partner of Beacon Pharmaceuticals Limited.
References
- ^ Chowdhury, Raihan M. (13 August 2012). "Bangladesh begins export of anti-cancer drugs". The Financial Express. Dhaka. Archived from the original on 25 August 2016. Retrieved 11 August 2016.
- ^ "Anti-cancer drugs now made in Bangladesh". The Daily Star. 23 February 2010.
- ^ Ahmed, Gazi Towhid (28 January 2015). "Beacon Pharma to invest Tk 290cr for expansion". The Daily Star.
- ^ http://www.secbd.org/ProspectusOfBeaconPharma.pdf Archived 2017-12-17 at the Wayback Machine, Securities and Exchange Commission (Bangladesh)
- ^ "Beacon Pharmaceuticals Limited". Dhaka Stock Exchange.
- ^ Rajagopal, Divya (27 July 2016). "US' Gilead faces competition from Bangladesh's Beacon pharma". The Economic Times. Mumbai.
- ^ "Home". beaconmedicare.com.bd.
External links
| This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's
terms of use. It may require cleanup to comply with Wikipedia's
content policies, particularly
neutral point of view. (July 2019) |
| Company type | Public |
|---|---|
| DSE: BEACONPHAR, CSE: BEACONPHAR | |
| Industry |
Pharmaceutics Biotechnology |
| Founded | 2006 |
| Headquarters | , Bangladesh |
Key people | Mohammad Ebadul Karim Bulbul, ( MD) |
| Products | Sofosvel, Darvoni, Tagrix, Crizonix, Daclavir, Soforal, Afanix, Axinix, Brigaix, Baricinix, Cabozanix, Dasanix, Hernix, Elbonix, Ibrutix, Lenvanix, Palbonix, Regonix, Tofacinix, and Wedica |
| Revenue | US$56 million (2019) |
| US$27 million (2019) | |
| US$4 million (2019) | |
| Total assets | US$100 million (2021 |
Number of employees | 4,000 (2021) |
| Website |
beaconpharma |
Beacon Pharmaceuticals PLC is a Bangladeshi pharmaceutical company that develops generic version of medications.
Beacon manufactures more than 200 generic drugs and 65 oncology products. Beacon is the first company in Bangladesh to start export of cancer drugs. [1] [2] The company is exporting its products to Asia, Africa, Europe and Latin America. Beacon is public limited company listed in Dhaka & Chittagong stock exchange. About 2000 people are working in this company. [3] [4] [5]
Beacon has introduced a number of global first generics. [6]
The company's commercially available products include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir, osimertinib, crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib, and trelagliptin.
BEACON Medicare Limited(BML) [7] is the exclusive global marketing & distribution partner of Beacon Pharmaceuticals Limited.
References
- ^ Chowdhury, Raihan M. (13 August 2012). "Bangladesh begins export of anti-cancer drugs". The Financial Express. Dhaka. Archived from the original on 25 August 2016. Retrieved 11 August 2016.
- ^ "Anti-cancer drugs now made in Bangladesh". The Daily Star. 23 February 2010.
- ^ Ahmed, Gazi Towhid (28 January 2015). "Beacon Pharma to invest Tk 290cr for expansion". The Daily Star.
- ^ http://www.secbd.org/ProspectusOfBeaconPharma.pdf Archived 2017-12-17 at the Wayback Machine, Securities and Exchange Commission (Bangladesh)
- ^ "Beacon Pharmaceuticals Limited". Dhaka Stock Exchange.
- ^ Rajagopal, Divya (27 July 2016). "US' Gilead faces competition from Bangladesh's Beacon pharma". The Economic Times. Mumbai.
- ^ "Home". beaconmedicare.com.bd.